| HOME >> BIOLOGY >> TECHNOLOGY |
Reconciliation to Non-GAAP Adjusted Cash Basis Amounts
(in $000s, except per share amounts)
Three Months Ended June 30, 2008
Non-GAAP
Adjusted
Non-GAAP Cash
GAAP Adjustments Basis (a)
Net revenue $401,127 $- $401,127
Cost of revenue 195,025 (17,225)(b)(c)(d)(e) 177,800
Gross profit 206,102 17,225 223,327
Gross margin 51% 56%
Operating expenses:
Research and development 29,808 (5,313)(b)(c)(d) 24,495
Selling, general and
administrative 172,792 (50,794)(b)(c)(d) 121,998
Total operating expenses 202,600 (56,107) 146,493
Operating income (loss) 3,502 73,332 76,834
Interest and other income
(expense), net (38,646) 6,624 (c) (32,022)
Income tax (benefit) provision (7,698) 23,066 (h) 15,368
Equity earnings of
unconsolidated entities,
net of tax (2,902) 6,199 (b)(c) 3,297
Net (loss) income $(30,348) $63,089 $32,741
Preferred stock dividends $(3,107) $(3,107)
Net (loss) income
available to common
stockholders - basic $(33,455) $29,634
Net (loss) income per
common share
Basic $(0.43) $0.38
Diluted $(0.43)(i)
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |